ID

42518

Description

Study ID: 106464 Clinical Study ID: 106464 Study Title: A Study of the Efficacy Against Episodes of Clinical Malaria Due to P. Falciparum Infection of GSK Biologicals Candidate Vaccine RTS, S/AS01, Administered According to a 0,1,2-months Schedule in Children Aged 5 to 17 Months Living in Tanzania & Kenya Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00380393 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: GSK malaria vaccine 257049 Vaccine, Sanofi-Pasteur's Human Diploid Cell Rabies Vaccine Trade Name: N/A Study Indication: Malaria ODM derived from https://clinicaltrials.gov/ct2/show/study/NCT00380393. This Phase IIb randomized, double-blind, controlled study of the efficacy against episodes of clinical malaria due to Plasmodium falciparum infection of GlaxoSmithKline Biologicals’ candidate vaccine RTS, S/AS01E, administered IM according to a 0, 1, 2-month vaccination schedule in children aged 5 months to 17 months living in Tanzania and Kenya. This study includes the following 7 clinical study visits (3 different visit types) during a double-blind phase (Day -60 to Month 6 1/2) and a single-blind phase including an extension for a subset of patients (month 7 to month 14). Clinical visit 1: Baseline visit, screening, and randomisation (DAY -60 to 0) Clinical visit 2: Vaccination I (MONTH 0, DAY 0 | DOSE 1 | 0 - 60 DAYS AFTER VISIT 1) Clinical visit 3: Vaccination II (MONTH 1, DAY 30 | DOSE 2 | 21 - 35 DAYS AFTER VISIT 2) Clinical visit 4: Vaccination III (MONTH 2, DAY 60 | DOSE 3 | 21 - 35 DAYS AFTER VISIT 3) Clinical visit 5: Blood Sample, ACD (MONTH 3, DAY 90 | 21 - 42 DAYS AFTER VISIT 4) Clinical visit 6: Blood Sample, ACD (MONTH 6 1/2 | CROSS-SECTIONAL VISIT FOR ACD | FINAL STUDY VISIT FOR DOUBLE-BLIND PHASE) Clinical visit 7: Blood Sample, ACD (MONTH 14 | FINAL STUDY VISIT SINGLE-BLIND PHASE) Field-worker home visits: During the vaccination period, clinical visits are accompanied by daily field-worker visits for a one-week period subsequent to each vaccine administration at clinical visits 2, 3, and 4 (visit code 21-26 following clinical visit 2; visit code 27-32 following clinical visit 3; visit code 33-38 following clinical visit 4). After completion of the vaccination period, clinical visits are then accompanied by weekly field-worker home visits (visit code 39-40 following clinical visit 4/dose 3; visit code 41-55 following clinical visit 5; visit code 56-86 following clinical visit 6). These visits serve the additional purpose of Active Case Detection (ACD). Passive Case Detection (PCD) for clinical malaria disease is performed both during the course of the double-blind (day -60 to month 6 1/2) and the single-blind phase (month 7 to month 14). Solicited and unsolicited adverse events form should be documented following vaccinations at visit 2 (dose 1), visit 3 (dose 2) and visit 4 (dose 3) whenever the subject experiences any of the listed signs/symptoms during the solicited period or any serious or non-serious unsolicited adverse events within 30 days post-vaccination. If any of these adverse events meets the protocol definition of serious, please complete a Serious Adverse Event report and fax to GSK Biologicals Study Contact for SAE reporting within 24 hours. Note that informed consent has to be obtained prior to any study procedure.

Lien

https://clinicaltrials.gov/ct2/show/study/NCT00380393

Mots-clés

Versions (1)
  1. 11/08/2021 11/08/2021 -
Détendeur de droits

GlaxoSmithKline

Téléchargé le

11 août 2021

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY-NC 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Efficacy of P. Falciparum Vaccine Against Malaria in Children NCT00380393

Anglais

Solicited and Unsolicited Adverse Events

1 Formulaires  
Administrative Documentation
Description

Administrative Documentation

Alias
UMLS CUI-1
C1320722
Vaccine dose number
Description

Vaccine dose number

Type de données

integer

Alias
UMLS CUI [1,1]
C1115464
UMLS CUI [1,2]
C0042210
Subject number
Description

Subject number

Type de données

integer

Alias
UMLS CUI [1]
C2348585
Date of visit/vaccination
Description

Visit date | vaccination date

Type de données

date

Alias
UMLS CUI [1]
C1320303
UMLS CUI [2,1]
C0042196
UMLS CUI [2,2]
C0011008
Solicited Adverse Events Local Symptoms
Description

Solicited Adverse Events Local Symptoms

Alias
UMLS CUI-1
C0877248
UMLS CUI-2
C1517001
UMLS CUI-3
C1457887
UMLS CUI-4
C0205276
UMLS CUI-5
C0150312
For each vaccine, has the subject experienced any of the following signs/symptoms at the administration site during the solicited period?
Description

If [Y] Yes, please tick No/Yes for each symptom. If Yes is ticked, please complete all respective items in the following two item groups. If any of these adverse events meets the protocol definition of serious, please complete a Serious Adverse Event report and fax to GSK Biologicals Study Contact for SAE reporting within 24 hours.

Type de données

text

Alias
UMLS CUI [1,1]
C0037088
UMLS CUI [1,2]
C2700396
UMLS CUI [1,3]
C0042196
UMLS CUI [1,4]
C0687676
Has the subject experienced swelling at the administration site during the solicited period?
Description

If yes is ticked, please complete all respective items in the following two item groups.

Type de données

boolean

Alias
UMLS CUI [1,1]
C0038999
UMLS CUI [1,2]
C2700396
UMLS CUI [1,3]
C0150312
Has the subject experienced pain at the administration site during the solicited period?
Description

If yes is ticked, please complete all respective items in the following two item groups.

Type de données

boolean

Alias
UMLS CUI [1,1]
C0030193
UMLS CUI [1,2]
C2700396
UMLS CUI [1,3]
C0150312
Solicited Adverse Events Local Symptoms
Description

Solicited Adverse Events Local Symptoms

Alias
UMLS CUI-1
C0877248
UMLS CUI-2
C1517001
UMLS CUI-3
C1457887
UMLS CUI-4
C0205276
UMLS CUI-5
C2348235
Day
Description

If symptom has been ticked in previous item group, please complete all respective items in this item group for day 0 to day 6 post vaccination.

Type de données

integer

Alias
UMLS CUI [1,1]
C0439228
UMLS CUI [1,2]
C0687676
UMLS CUI [1,3]
C0042196
Swelling, size (mm)
Description

Only to be completed if swelling has been selected in previous item group.

Type de données

integer

Unités de mesure
  • mm
Alias
UMLS CUI [1,1]
C0038999
UMLS CUI [1,2]
C0456389
UMLS CUI [1,3]
C2700396
mm
Pain intensity
Description

Please indicate the intensity for solicited symptoms (pain). Only to be completed if pain has been selected in previous item group.

Type de données

integer

Alias
UMLS CUI [1,1]
C0518690
UMLS CUI [1,2]
C0030193
UMLS CUI [1,3]
C2700396
Solicited Adverse Events Local Symptoms
Description

Solicited Adverse Events Local Symptoms

Alias
UMLS CUI-1
C0877248
UMLS CUI-2
C1517001
UMLS CUI-3
C1457887
UMLS CUI-4
C0205276
UMLS CUI-5
C0449238
Local Symptom
Description

If symptom details have been quantified in the previous item group, please select the respective symptom and complete all items in this item group.

Type de données

text

Alias
UMLS CUI [1,1]
C1457887
UMLS CUI [1,2]
C0205276
Did the patient experience ongoing local symptoms after day 6?
Description

If yes, please indicate the date of the last day of symptoms in the following item.

Type de données

boolean

Alias
UMLS CUI [1,1]
C1457887
UMLS CUI [1,2]
C2700396
UMLS CUI [1,3]
C0549178
Date of the last day of symptoms
Description

Date in time last symptoms

Type de données

date

Alias
UMLS CUI [1,1]
C0011008
UMLS CUI [1,2]
C1517741
UMLS CUI [1,3]
C1457887
Solicited Adverse Events General Symptoms
Description

Solicited Adverse Events General Symptoms

Alias
UMLS CUI-1
C0877248
UMLS CUI-2
C1517001
UMLS CUI-3
C0159028
UMLS CUI-4
C0150312
For each vaccine, has the subject experienced any of the following signs/symptoms at the administration site during the solicited period?
Description

If [Y] Yes, please tick No/Yes for each symptom. If Yes is ticked, please complete all respective items in the following two item groups. If any of these adverse events meets the protocol definition of serious, please complete a Serious Adverse Event report and fax to GSK Biologicals Study Contact for SAE reporting within 24 hours.

Type de données

text

Alias
UMLS CUI [1,1]
C0037088
UMLS CUI [1,2]
C0687676
UMLS CUI [1,3]
C0042196
Has the subject experienced fever [FE] during the solicited period?
Description

Fever is defined as axillary temperature > 37.5°C, oral temperature > 37.5°C, or rectal temperature > 38.0°C. If yes is ticked, please complete all respective items in the following two item groups.

Type de données

boolean

Alias
UMLS CUI [1,1]
C0015967
UMLS CUI [1,2]
C0150312
Body temperature measurement site
Description

Please consider axillary measurement [A] to be the preferable route.

Type de données

text

Alias
UMLS CUI [1,1]
C0005903
UMLS CUI [1,2]
C0449687
Has the subject experienced irritability/fussiness [IR] during the solicited period?
Description

If yes is ticked, please complete all respective items in the following two item groups.

Type de données

boolean

Alias
UMLS CUI [1,1]
C0022107
UMLS CUI [1,2]
C0150312
Has the subject experienced drowsiness [DR] during the solicited period?
Description

If yes is ticked, please complete all respective items in the following two item groups.

Type de données

boolean

Alias
UMLS CUI [1,1]
C0013144
UMLS CUI [1,2]
C0150312
Has the subject experienced loss of appetite [LO] during the solicited period?
Description

If yes is ticked, please complete all respective items in the following two item groups.

Type de données

boolean

Alias
UMLS CUI [1,1]
C1971624
UMLS CUI [1,2]
C0150312
Solicited Adverse Events General Symptoms
Description

Solicited Adverse Events General Symptoms

Alias
UMLS CUI-1
C0877248
UMLS CUI-2
C1517001
UMLS CUI-3
C0159028
UMLS CUI-4
C2348235
Day
Description

If symptom has been ticked in previous item group, please complete all respective items in this item group for day 0 to day 6 post vaccination.

Type de données

integer

Alias
UMLS CUI [1,1]
C0439228
UMLS CUI [1,2]
C0687676
UMLS CUI [1,3]
C0042196
Body temperature
Description

Only to be completed if Fever [FE] has been selected in previous item group.

Type de données

float

Unités de mesure
  • °C
Alias
UMLS CUI [1,1]
C0005903
UMLS CUI [1,2]
C0449687
°C
Body temperature not taken
Description

Only to be completed if [FE] has been selected in previous item group.

Type de données

boolean

Alias
UMLS CUI [1,1]
C0005903
UMLS CUI [1,2]
C1272696
Irritability/Fussiness intensity
Description

Only to be completed if Irritability/Fussiness [IR] has been selected in previous item group. Please indicate the intensity for solicited symptoms (irritability / fussiness).

Type de données

integer

Alias
UMLS CUI [1,1]
C0518690
UMLS CUI [1,2]
C0022107
Drowsiness intensity
Description

Only to be completed if drowsiness [DR] has been selected in previous item group. Please indicate the intensity for solicited symptoms (drowsiness).

Type de données

integer

Alias
UMLS CUI [1,1]
C0518690
UMLS CUI [1,2]
C0013144
Loss of appetite intensity
Description

Only to be completed if loss of appetite [LO] has been selected in previous item group. Please indicate the intensity for solicited symptoms (loss of appetite).

Type de données

integer

Alias
UMLS CUI [1,1]
C0518690
UMLS CUI [1,2]
C1971624
Solicited Adverse Events General Symptoms
Description

Solicited Adverse Events General Symptoms

Alias
UMLS CUI-1
C0877248
UMLS CUI-2
C1517001
UMLS CUI-3
C0159028
UMLS CUI-4
C0449238
Symptom
Description

If symptom details have been quantified in the previous item group, please select the respective symptom and complete all items in this item group.

Type de données

text

Alias
UMLS CUI [1]
C0159028
Did the patient experience ongoing symptoms after day 6?
Description

If yes, please indicate the date of the last day of symptoms in the following item.

Type de données

boolean

Alias
UMLS CUI [1,1]
C1457887
UMLS CUI [1,2]
C0549178
Date of the last day of symptoms
Description

Date in time last symptoms

Type de données

date

Alias
UMLS CUI [1,1]
C0011008
UMLS CUI [1,2]
C1517741
UMLS CUI [1,3]
C1457887
Causality?
Description

Please indicate the suspected causality between the vaccination and the selected symptom. Note that for Fever [FE], any Grade 3 temperature not related to vaccination should be entered as Causality “NO”. Alternative reasoning should be given in the following item.

Type de données

text

Alias
UMLS CUI [1,1]
C0015127
UMLS CUI [1,2]
C0015967
UMLS CUI [2,1]
C0015127
UMLS CUI [2,2]
C0022107
UMLS CUI [3,1]
C0015127
UMLS CUI [3,2]
C0013144
UMLS CUI [4,1]
C0015127
UMLS CUI [4,2]
C1971624
Please describe an alternative reason for any Grade 3 temperature not related to vaccination (temperature > 39°C; Causality “NO”).
Description

Note: This item should only be completed if fever (>39°C) non-related to vaccination (Causality “NO” in previous item) has occured.

Type de données

text

Alias
UMLS CUI [1,1]
C0015127
UMLS CUI [1,2]
C0015967
Unsolicited Adverse Events
Description

Unsolicited Adverse Events

Alias
UMLS CUI-1
C0877248
UMLS CUI-2
C4055646
Has the subject experienced any serious or non-serious unsolicited adverse events within 30 days post-vaccination?
Description

If [Y] Yes, fill in the Non-Serious Adverse Event section or Serious Adverse Event report, as appropriate.

Type de données

text

Alias
UMLS CUI [1,1]
C1519255
UMLS CUI [1,2]
C4055646
UMLS CUI [1,3]
C0687676
UMLS CUI [1,4]
C0042196
UMLS CUI [2,1]
C1518404
UMLS CUI [2,2]
C4055646
UMLS CUI [2,3]
C0687676
UMLS CUI [2,4]
C0042196
Retour au début de la page

Similar models

Solicited and Unsolicited Adverse Events

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
Administrative Documentation
C1320722 (UMLS CUI-1)
Item
Vaccine dose number
integer
C1115464 (UMLS CUI [1,1])
C0042210 (UMLS CUI [1,2])
Visit number
Code List
Vaccine dose number
CL Item
dose 1 (visit 2) (1)
CL Item
dose 2 (visit 3) (2)
CL Item
dose 3 (visit 4) (3)
Subject number
Item
Subject number
integer
C2348585 (UMLS CUI [1])
Visit date | vaccination date
Item
Date of visit/vaccination
date
C1320303 (UMLS CUI [1])
C0042196 (UMLS CUI [2,1])
C0011008 (UMLS CUI [2,2])
Item Group
Solicited Adverse Events Local Symptoms
C0877248 (UMLS CUI-1)
C1517001 (UMLS CUI-2)
C1457887 (UMLS CUI-3)
C0205276 (UMLS CUI-4)
C0150312 (UMLS CUI-5)
Item
For each vaccine, has the subject experienced any of the following signs/symptoms at the administration site during the solicited period?
text
C0037088 (UMLS CUI [1,1])
C2700396 (UMLS CUI [1,2])
C0042196 (UMLS CUI [1,3])
C0687676 (UMLS CUI [1,4])
For each vaccine, has the subject experienced any of the following signs/symptoms at the administration site during the solicited period?
Code List
For each vaccine, has the subject experienced any of the following signs/symptoms at the administration site during the solicited period?
CL Item
Information not available ([U])
CL Item
No Vaccine administered ([NA])
CL Item
No ([N])
CL Item
Yes ([Y])
Swelling injection site
Item
Has the subject experienced swelling at the administration site during the solicited period?
boolean
C0038999 (UMLS CUI [1,1])
C2700396 (UMLS CUI [1,2])
C0150312 (UMLS CUI [1,3])
Pain injection site
Item
Has the subject experienced pain at the administration site during the solicited period?
boolean
C0030193 (UMLS CUI [1,1])
C2700396 (UMLS CUI [1,2])
C0150312 (UMLS CUI [1,3])
Item Group
Solicited Adverse Events Local Symptoms
C0877248 (UMLS CUI-1)
C1517001 (UMLS CUI-2)
C1457887 (UMLS CUI-3)
C0205276 (UMLS CUI-4)
C2348235 (UMLS CUI-5)
Day post vaccination
Item
Day
integer
C0439228 (UMLS CUI [1,1])
C0687676 (UMLS CUI [1,2])
C0042196 (UMLS CUI [1,3])
Swelling size injection site
Item
Swelling, size (mm)
integer
C0038999 (UMLS CUI [1,1])
C0456389 (UMLS CUI [1,2])
C2700396 (UMLS CUI [1,3])
Item
Pain intensity
integer
C0518690 (UMLS CUI [1,1])
C0030193 (UMLS CUI [1,2])
C2700396 (UMLS CUI [1,3])
Symptom intensity pain injection site
Code List
Pain intensity
CL Item
Absent (0)
CL Item
Minor reaction to touch (1)
CL Item
Cries / protests on touch (2)
CL Item
Cries when limb is moved / spontaneously painful (3)
Item Group
Solicited Adverse Events Local Symptoms
C0877248 (UMLS CUI-1)
C1517001 (UMLS CUI-2)
C1457887 (UMLS CUI-3)
C0205276 (UMLS CUI-4)
C0449238 (UMLS CUI-5)
Item
Local Symptom
text
C1457887 (UMLS CUI [1,1])
C0205276 (UMLS CUI [1,2])
Local Symptom
Code List
Local Symptom
CL Item
Swelling ([SW])
CL Item
Pain ([PA])
Symptoms injection site continuous
Item
Did the patient experience ongoing local symptoms after day 6?
boolean
C1457887 (UMLS CUI [1,1])
C2700396 (UMLS CUI [1,2])
C0549178 (UMLS CUI [1,3])
Date in time last symptoms
Item
Date of the last day of symptoms
date
C0011008 (UMLS CUI [1,1])
C1517741 (UMLS CUI [1,2])
C1457887 (UMLS CUI [1,3])
Item Group
Solicited Adverse Events General Symptoms
C0877248 (UMLS CUI-1)
C1517001 (UMLS CUI-2)
C0159028 (UMLS CUI-3)
C0150312 (UMLS CUI-4)
Item
For each vaccine, has the subject experienced any of the following signs/symptoms at the administration site during the solicited period?
text
C0037088 (UMLS CUI [1,1])
C0687676 (UMLS CUI [1,2])
C0042196 (UMLS CUI [1,3])
For each vaccine, has the subject experienced any of the following signs/symptoms at the administration site during the solicited period?
Code List
For each vaccine, has the subject experienced any of the following signs/symptoms at the administration site during the solicited period?
CL Item
Information not available ([U])
CL Item
No Vaccine administered ([NA])
CL Item
No ([N])
CL Item
Yes ([Y])
Fever [FE]
Item
Has the subject experienced fever [FE] during the solicited period?
boolean
C0015967 (UMLS CUI [1,1])
C0150312 (UMLS CUI [1,2])
Item
Body temperature measurement site
text
C0005903 (UMLS CUI [1,1])
C0449687 (UMLS CUI [1,2])
Body temperature measurement site
Code List
Body temperature measurement site
CL Item
Axillary (preferred) ([A])
CL Item
Oral ([O])
CL Item
Rectal ([R])
Irritability/Fussiness [IR]
Item
Has the subject experienced irritability/fussiness [IR] during the solicited period?
boolean
C0022107 (UMLS CUI [1,1])
C0150312 (UMLS CUI [1,2])
Drowsiness [DR]
Item
Has the subject experienced drowsiness [DR] during the solicited period?
boolean
C0013144 (UMLS CUI [1,1])
C0150312 (UMLS CUI [1,2])
Loss of appetite [LO]
Item
Has the subject experienced loss of appetite [LO] during the solicited period?
boolean
C1971624 (UMLS CUI [1,1])
C0150312 (UMLS CUI [1,2])
Item Group
Solicited Adverse Events General Symptoms
C0877248 (UMLS CUI-1)
C1517001 (UMLS CUI-2)
C0159028 (UMLS CUI-3)
C2348235 (UMLS CUI-4)
Day post vaccination
Item
Day
integer
C0439228 (UMLS CUI [1,1])
C0687676 (UMLS CUI [1,2])
C0042196 (UMLS CUI [1,3])
Body temperature
Item
Body temperature
float
C0005903 (UMLS CUI [1,1])
C0449687 (UMLS CUI [1,2])
Body temperature not done
Item
Body temperature not taken
boolean
C0005903 (UMLS CUI [1,1])
C1272696 (UMLS CUI [1,2])
Item
Irritability/Fussiness intensity
integer
C0518690 (UMLS CUI [1,1])
C0022107 (UMLS CUI [1,2])
Irritability/Fussiness intensity
Code List
Irritability/Fussiness intensity
CL Item
Behavior as usual (0)
CL Item
Crying more than usual / no effect on normal activity (1)
CL Item
Crying more than usual / interferes with normal activity (2)
CL Item
Crying that cannot be comforted / prevents normal activity (3)
Item
Drowsiness intensity
integer
C0518690 (UMLS CUI [1,1])
C0013144 (UMLS CUI [1,2])
Symptom intensity drowsiness
Code List
Drowsiness intensity
CL Item
Behavior as usual (0)
CL Item
Drowsiness easily tolerated (1)
CL Item
Drowsiness that interferes with normal activity (2)
CL Item
Drowsiness that prevents normal activity (3)
Item
Loss of appetite intensity
integer
C0518690 (UMLS CUI [1,1])
C1971624 (UMLS CUI [1,2])
Symptom intensity loss of appetite
Code List
Loss of appetite intensity
CL Item
Appetite as usual (0)
CL Item
Eating less than usual / no effect on normal activity (1)
CL Item
Eating less than usual / interferes with normal activity (2)
CL Item
Not eating at all (3)
Item Group
Solicited Adverse Events General Symptoms
C0877248 (UMLS CUI-1)
C1517001 (UMLS CUI-2)
C0159028 (UMLS CUI-3)
C0449238 (UMLS CUI-4)
Item
Symptom
text
C0159028 (UMLS CUI [1])
Local Symptom
Code List
Symptom
CL Item
Fever ([FE])
CL Item
Irritability/Fussiness ([IR])
CL Item
Drowsiness ([DR])
CL Item
Loss of appetite ([LO])
Symptoms continuous
Item
Did the patient experience ongoing symptoms after day 6?
boolean
C1457887 (UMLS CUI [1,1])
C0549178 (UMLS CUI [1,2])
Date in time last symptoms
Item
Date of the last day of symptoms
date
C0011008 (UMLS CUI [1,1])
C1517741 (UMLS CUI [1,2])
C1457887 (UMLS CUI [1,3])
Etiology aspects fever | irritable mood | drowsiness | loss of appetite
Item
Causality?
text
C0015127 (UMLS CUI [1,1])
C0015967 (UMLS CUI [1,2])
C0015127 (UMLS CUI [2,1])
C0022107 (UMLS CUI [2,2])
C0015127 (UMLS CUI [3,1])
C0013144 (UMLS CUI [3,2])
C0015127 (UMLS CUI [4,1])
C1971624 (UMLS CUI [4,2])
Etiology aspects fever
Item
Please describe an alternative reason for any Grade 3 temperature not related to vaccination (temperature > 39°C; Causality “NO”).
text
C0015127 (UMLS CUI [1,1])
C0015967 (UMLS CUI [1,2])
Item Group
Unsolicited Adverse Events
C0877248 (UMLS CUI-1)
C4055646 (UMLS CUI-2)
Item
Has the subject experienced any serious or non-serious unsolicited adverse events within 30 days post-vaccination?
text
C1519255 (UMLS CUI [1,1])
C4055646 (UMLS CUI [1,2])
C0687676 (UMLS CUI [1,3])
C0042196 (UMLS CUI [1,4])
C1518404 (UMLS CUI [2,1])
C4055646 (UMLS CUI [2,2])
C0687676 (UMLS CUI [2,3])
C0042196 (UMLS CUI [2,4])
For each vaccine, has the subject experienced any of the following signs/symptoms at the administration site during the solicited period?
Code List
Has the subject experienced any serious or non-serious unsolicited adverse events within 30 days post-vaccination?
CL Item
Information not available ([U])
CL Item
No Vaccine administered ([NA])
CL Item
No ([N])
CL Item
Yes ([Y])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial